全文获取类型
收费全文 | 13054篇 |
免费 | 1138篇 |
国内免费 | 311篇 |
专业分类
耳鼻咽喉 | 97篇 |
儿科学 | 179篇 |
妇产科学 | 403篇 |
基础医学 | 337篇 |
口腔科学 | 65篇 |
临床医学 | 1253篇 |
内科学 | 1239篇 |
皮肤病学 | 31篇 |
神经病学 | 267篇 |
特种医学 | 297篇 |
外国民族医学 | 1篇 |
外科学 | 1226篇 |
综合类 | 1731篇 |
预防医学 | 448篇 |
眼科学 | 41篇 |
药学 | 1462篇 |
10篇 | |
中国医学 | 384篇 |
肿瘤学 | 5032篇 |
出版年
2024年 | 19篇 |
2023年 | 114篇 |
2022年 | 314篇 |
2021年 | 440篇 |
2020年 | 368篇 |
2019年 | 349篇 |
2018年 | 420篇 |
2017年 | 432篇 |
2016年 | 475篇 |
2015年 | 458篇 |
2014年 | 1028篇 |
2013年 | 866篇 |
2012年 | 886篇 |
2011年 | 1014篇 |
2010年 | 818篇 |
2009年 | 845篇 |
2008年 | 792篇 |
2007年 | 740篇 |
2006年 | 643篇 |
2005年 | 501篇 |
2004年 | 370篇 |
2003年 | 388篇 |
2002年 | 267篇 |
2001年 | 299篇 |
2000年 | 249篇 |
1999年 | 238篇 |
1998年 | 157篇 |
1997年 | 138篇 |
1996年 | 122篇 |
1995年 | 135篇 |
1994年 | 83篇 |
1993年 | 81篇 |
1992年 | 50篇 |
1991年 | 46篇 |
1990年 | 35篇 |
1989年 | 25篇 |
1988年 | 29篇 |
1987年 | 26篇 |
1986年 | 22篇 |
1985年 | 40篇 |
1984年 | 39篇 |
1983年 | 18篇 |
1982年 | 30篇 |
1981年 | 18篇 |
1980年 | 24篇 |
1979年 | 30篇 |
1978年 | 9篇 |
1977年 | 6篇 |
1976年 | 3篇 |
1969年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
目的分析成人血液系统恶性肿瘤患者接受强烈化疗后中性粒细胞减少性肠炎(NE)的发生率、危险因素及预后情况。方法收集2004至2013年接受化疗的1804例血液系统恶性肿瘤患者,记录患者血常规、凝血检测和血液生化检测结果,并记录患者年龄、性别、原发病、既往化疗次数、既往化疗方案中是否使用阿糖胞苷、临床症状、肠壁厚度、中性粒细胞最低计数、中性粒细胞缺乏持续时间、NE的治疗方法和预后等,探讨NE起病诱因、临床特征、腹部B超特点、症状的预后意义及化疗药物对发病的影响等。结果1804例患者中226例(12.5%)化疗后合并NE,化疗后10~19d起病,中位起病时间为化疗后第14天。发生NE后26例患者死亡,病死率11.5%。化疗药物包括阿糖胞苷、临床症状≥4项、中性粒细胞缺乏持续超过7d以及B超下肠壁厚度≥10mm的患者病死率相对较高。结论NE是接受强烈化疗的血液系统肿瘤患者的严重的并发症,发生NE后患者病死率较高。 相似文献
3.
《Urologic oncology》2015,33(5):217-225
Although both surgery and radiation are potential curative options for men with clinically localized prostate cancer, a significant proportion of men with high-risk and locally advanced disease will demonstrate biochemical and potentially clinical progression of their disease. Neoadjuvant systemic therapy before radical prostatectomy (RP) is a logical strategy to improve treatment outcomes for men with clinically localized high-risk prostate cancer. Furthermore, delivery of chemotherapy and other systemic agents before RP affords an opportunity to explore the efficacy of these agents with pathologic end points.Neoadjuvant chemotherapy, primarily with docetaxel (with or without androgen deprivation therapy), has demonstrated feasibility and safety in men undergoing RP, but no study to date has established the efficacy of neoadjuvant chemotherapy or neoadjuvant chemohormonal therapies. Other novel agents, such as those targeting the vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, clusterin, and immunomodulatory therapeutics, are currently under investigation. 相似文献
4.
5.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2020,32(6):347-353
The current COVID-19 pandemic presents a substantial obstacle to cancer patient care. Data from China as well as risk models suppose that cancer patients, particularly those on active, immunosuppressive therapies are at higher risks of severe infection from the illness. In addition, staff illness and restructuring of services to deal with the crisis will inevitably place treatment capacities under significant strain. These guidelines aim to expand on those provided by NHS England regarding cancer care during the coronavirus pandemic by examining the known literature and provide guidance in managing patients with urothelial and rarer urinary tract cancers. In particular, they address the estimated risk and benefits of standard treatments and consider the alternatives in the current situation. As a result, it is recommended that this guidance will help form a framework for shared decision making with patients. Moreover, they do not advise a one-size-fits-all approach but recommend continual assessment of the situation with discussion within and between centres. 相似文献
6.
7.
Biliary tract cancer, including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are rare tumours with a rising incidence. Prognosis is poor, since most patients are diagnosed with advanced disease. Only ~20% of patients are diagnosed with early-stage disease, suitable for curative surgery. Despite surgery performed with potentially-curative intent, relapse rates are high, with around 60–70% of patients expected to have disease recurrence. Most relapses occur in the form of distant metastases, with a predominance of liver spread. In view of high tumour recurrence, adjuvant strategies have been explored for many years, in the form of radiotherapy, chemo-radiotherapy and chemotherapy. Historically, few randomised trials were available, which included a variety of additional tumours (e.g. pancreatic and ampullary tumours); most evidence relied on phase II and retrospective studies, with no high-quality evidence available to define the real benefit derived from adjuvant strategies.Since 2017, three randomised phase III clinical trials have been reported; all recruited patients with resected biliary tract cancer (CCA and GBC) who were randomised to observation alone, or chemotherapy in the form of gemcitabine (BCAT study; included patients diagnosed with extrahepatic CCA only), gemcitabine and oxaliplatin (PRODIGE-12/ACCORD-18; included patients diagnosed with CCA and GBC) or capecitabine (BILCAP; included patients diagnosed with CCA and GBC). While gemcitabine-based chemotherapy failed to show an impact on patient outcome (relapse-free survival (RFS) or overall survival (OS)), the BILCAP study showed a benefit from adjuvant capecitabine in terms of OS (pre-planned sensitivity analysis in the intention-to-treat population and in the per-protocol analysis), with confirmed benefit in terms of RFS. Based on the BILCAP trial, international guidelines recommend adjuvant capecitabine for a period of six months following potentially curative resection of CCA as the current standard of care for resected CCA and GBC. However, BILCAP failed to show OS benefit in the intention-to-treat (non-sensitivity analysis) population (primary end-point), and this finding, as well as some inconsistencies between studies has been criticised and has led to confusion in the biliary tract cancer medical community.This review summarises the adjuvant field in biliary tract cancer, with evidence before and after 2017, and comparison between the latest randomised phase III studies. Potential explanations are presented for differential findings, and future steps are explored. 相似文献
8.
食管癌热疗、放疗、化疗三联治疗的前瞻性研究 总被引:12,自引:1,他引:11
目的 分析热疗、放疗、化疗三联治疗食管癌的疗效。及与放疗比较。材料与方法 1987年6月至1991年10月,对食管癌的三联治疗和常规放疗进行前瞻性随机研究。两组病例分别为57例和58例,三联组放疗每周2次,每次3.6Gy,总量36Gy,5周,化疗:平阳霉素20mg,顺铂(DDP)1.0-1.5mg/kg,每周1次,共3次,腔内微波热疗每周1次,共3-5次,全部病例随访5年以上,失访者按死亡统计。结果 总生存率:三联组1,3,5年分别为93.0%(53/57)、40.4%(23/57)、31.6%(18/57)。单放组分别为:79.3%(46/58)、31.0%(18/58)、15.5%(9/58)。1,5年生存率的P<0.05,其中病变长度在5cm以上的:三联组1,3,5年生存率分别为91.4%(32/35)、51.4%(18/35)、40.0%(14/35);单放组为78.8%(26/33)、24.2%(8/33)、12.1%(4/33),三联组月逐年均优于单放组,T90<43℃的为90.0%((/10).20.0%(2/10),及0(0/10),而T90>43℃的分别为92.8%(39/42),42.8%(18/42)及38.1%(16/42)。结论 食管癌三联治疗在减少了放疗剂量的同时,提高了近期疗效和1,3,5年生存率。 相似文献
9.
白血病病人骨髓抑制期实施防感染措施时机的研究 总被引:5,自引:0,他引:5
目的 :研究白血病病人在化疗期间 ,不同时间实施预防感染护理的效果。方法 :对照组在化学疗法结束后给予预防感染的护理措施 ,实验组在化学疗法开始前 3~ 7d实施预防性护理措施。观察两组病人感染发生率。结果 :感染发生率实验组明显低于观察组。结论 :在化学疗法开始前实施预防性护理措施有助于降低感染发生率 相似文献
10.
Z. Malazgirt K. Topgul S. Sokmen S. Ersin A. G. Turkcapar H. Gok N. Gonullu M. Paksoy M. Ertem 《Hernia》2006,10(4):326-330
Most of the papers published on spigelian hernia are either case reports or small retrospective series. In this prospective
multicenter study, we aimed to outline the specific features of spigelian hernias and patients’ characteristics more clearly.
Surgeons enrolled patients to be entered into the database as they diagnosed and treated the hernias at will. The baseline
and surgical outcome parameters were noted in each patient. A painful mass was the main presenting complaint in half of 34
patients. Accurate preoperative diagnosis was possible in 31 patients. Open intraperitoneal mesh repair was the preferred
technique. The mean hospital stay and time until return to normal daily activities were 4.1 and 15.6 days. Although a rare
condition, diagnosis of a spigelian hernia is not difficult once remembered. Its surgical repair seems to cause few complications
and is very well tolerated by the patient. 相似文献